Evox Therapeutics Ltd, a leading exosome therapeutics company, announced advances in exosome engineering, manufacturing, and tissue targeting at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France. The company’s nine presentations highlight the progress Evox has made in modulating exosome pharmacokinetics through extension of circulation half-life and improved tissue-targeting via display of ligands on the exosome surface. Other advances in exosome manufacture, in vivo production, and exosome biology were also presented. “Exosomes have significant potential as a new therapeutic modality to treat a number of diseases by enabling broader use of a variety of drug payloads including proteins and nucleic acids,” said Antonin de Fougerolles, PhD, Chief Executive Officer of Evox Therapeutics. “As demonstrated by our presentations, we are making good progress in engineering exosomes that possess desired drug-like attributes such as tissue targeting and extended circulation half-life. In parallel, we are also focused on advances in exosome manufacturing, including exploring new ways to produce exosome therapeutics. We believe our advances will allow exosome therapeutics access to cellular compartments and tissues that are currently out of reach using other approaches.”